MYRIP

Across TCGA pan-cancer cohorts, MYRIP mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MYRIP data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MYRIP mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MYRIP expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where MYRIP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	0.221	1.000	.005	24	view →
HNSC	OS	Tertile	All	0.631	1.000	.038	16	view →
PDAC	OS	Quartile	II,III,IV	1.000	0.639	.012	10	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MYRIP–LUAD (OS)

Open the LUAD breakdown →